Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Adults who are not taking a GLP-1 medication but want broad micronutrient coverage without supplemental iron
People with a history of cancer should discuss the potential risks and benefits of semaglutide use with their healthcare provider
Specifically, GLP-1s appear to dampen activity in reward-related regions like the nucleus accumbens, which plays a key role in cravings, dopamine release, and conditioned food responses
Analyzing medical and outpatient pharmacy claims, the researchers found that semaglutide use was associated with a 49% lower adjusted hazard of COVID-19-associated mortality, especially relevant since obesity or overweight and type 2 diabetes, the primary conditions for which semaglutide may be prescribed, have consistently been associated with an increased mortality risk
RETA treatment improved metabolic factors, boosted anti-tumor immunity, and potently blunted tumor progression in non-obesity associated lung adenocarcinoma Based on the dramatic findings in PDAC, an obesity-associated cancer, we were interested in whether RETA could also be effective in a non-obesity associated cancer
Unlike SGLT2 inhibitors, tirzepatide does not increase glucose in urine and clinical trials found no elevated UTI risk compared to placebo
